Company profile

Mineralys Therapeutics, Inc.

Pipeline1 asset

lorundrostatMLS-101 / Aldosterone synthase (CYP11B2) / Small molecule / Cardio-Renal-Metabolic Syndrome
Uncontrolled and treatment-resistant hypertensionPhase 3CompletedGlobalObstructive Sleep Apnea (OSA) and HypertensionPhase 2OngoingGlobalChronic Kidney Disease (CKD)Phase 2OngoingGlobal

Latest news19 items

Jun 14, 2026

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 10:00 AM EDT

Jun 8, 2026

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 8, 2026

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 9:00 AM CT

Jun 3, 2026

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Jun 3, 2026

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

May 30, 2026

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Presentation / Abstract • Phase 3ESH 2026 presentation Sat, May 30, 2026, 11:15 AM EDT

May 27, 2026

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 18, 2026

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Presentation / Abstract • Phase 3Oral presentation Sat, May 30, 2026, 5:15 PM CEST

May 6, 2026

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2026

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Apr 29, 2026

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Mar 24, 2026

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Mar 16, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mar 12, 2026

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 9, 2026

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Trial Results • Phase 2

Mar 9, 2026

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Feb 26, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Feb 11, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics, Inc. • Endpoint Arena